Despite remdesivir approval and 2 big buyouts, Gilead CEO Dan O'Day sees pay fall 35% from 2019
For all intents and purposes, 2020 was a busy year for Gilead. The big biotech pulled off two big acquisitions in Forty Seven and Immunomedics, continued seeing growth in HIV products despite expiring patents on Truvada and won the Covid-19 treatment race with a sharp pivot to remdesivir early in the year, despite remaining skepticism over the drug’s effectiveness.
In spite of all that, CEO Dan O’Day saw his compensation fall dramatically from 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.